Development · 24 Sep 2026
2 publishers have reported this development. Each act of reporting is below, cited.
Net profit of Symbiotec Pharmalab declined 53.01% to Rs 14.06 crore in the quarter ended June 2026 as against Rs 29.92 crore during the previous quarter ended June 2025.
Symbiotec Pharmalab reported a 52.8% fall in consolidated net profit to Rs 14.1 crore in Q1 FY27 compared to Q1 FY26.
Symbiotec Pharmalab has reported a 52.8% fall in consolidated net profit to Rs 14.1 crore despite a 7% rise in revenue from operations to Rs 218.2 crore in Q1 FY27 as compared with Q1 FY26.
Symbiotec Pharmalab's latest consolidated quarterly numbers were disappointing, with the top line growing 7 percent year-over-year while net profit nearly halved.
Symbiotec Pharmalab's latest consolidated quarterly numbers showed a 7 percent year-over-year increase in the top line, while net profit nearly halved.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.